Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review.
Breast carcinoma
Hypofractionated radiotherapy
Radiotherapy
Simultaneous integrated boost
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
21
03
2022
revised:
18
04
2022
accepted:
11
05
2022
pubmed:
25
5
2022
medline:
25
5
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
Several studies have shown that simultaneous integrated boost provides better dose homogeneity, improves the biologically effective dose-volume histogram and reduces treatment time compared to sequential boost in breast cancer. We conducted a systematic review of published trials evaluating simultaneous integrated boost in hypofractionated radiotherapy to analyze the results in terms of overall survival, local control, early and late side effects, and radiotherapy techniques used. Upon 9 articles, the prescribed dose to the whole breast varied from 40 to 46.8 Gy. The number of fractions varies from 15 to 20 fractions. The prescribed dose per fraction to the boost varied from 2.4 Gy per fraction to 3.4 Gy per fraction for a total boost dose from 48 to 52.8 Gy. Simultaneous integrated boost seems effective and safe when given hypofractionated whole-breast irradiation but needs to be validated in prospective trials.
Identifiants
pubmed: 35609442
pii: S1936-5233(22)00115-2
doi: 10.1016/j.tranon.2022.101456
pmc: PMC9125620
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
101456Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Références
BMC Cancer. 2012 Oct 25;12:495
pubmed: 23098579
J Cancer Res Clin Oncol. 2014 Jan;140(1):167-77
pubmed: 24292425
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Lancet Oncol. 2022 Jan;23(1):e21-e31
pubmed: 34973228
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet. 2008 Mar 29;371(9618):1098-107
pubmed: 18355913
Radiat Oncol. 2015 Jul 09;10:139
pubmed: 26156086
J Egypt Natl Canc Inst. 2017 Mar;29(1):39-45
pubmed: 28343538
Radiat Oncol. 2012 Aug 28;7:145
pubmed: 22929062
Cancer Radiother. 2016 Sep;20 Suppl:S139-46
pubmed: 27522187
Biomed Res Int. 2014;2014:827475
pubmed: 25162031
Breast J. 2020 Oct;26(10):1946-1952
pubmed: 32648331
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Radiother Oncol. 2021 May;158:62-66
pubmed: 33617910
Strahlenther Onkol. 2014 Jul;190(7):646-53
pubmed: 24737540
Radiat Oncol. 2016 Sep 17;11(1):120
pubmed: 27639373
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Strahlenther Onkol. 2021 Jan;197(1):48-55
pubmed: 33001241
Radiat Oncol. 2012 Jun 01;7:80
pubmed: 22656865